References
- Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–260.
- Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-477.
- Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:2032–2042. doi:https://doi.org/10.1056/NEJMoa1908419.
- Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, Van Meijeren C, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392:940–949.
- Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol 2019;4:1092–1101. doi:https://doi.org/10.1001/jamacardio.2019.3355.
- Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745–754. doi:https://doi.org/10.1161/CIRCULATIONAHA.106.686048.
- Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 2018;15:480–496. doi:https://doi.org/10.1038/s41569-018-0049-1.
- Ho P, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008;299:532–539. doi:https://doi.org/10.1001/jama.299.5.532.
- Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, Lopez-Sendon J, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 2016;37:1133-1142.
- Reejhsinghani R, Lotfi AS. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015;11:93–106.
- Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED, et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). Circulation 2018;138:1290–1300. doi:https://doi.org/10.1161/CIRCULATIONAHA.118.034790.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057. doi:https://doi.org/10.1056/NEJMoa0904327.
- Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800. doi:https://doi.org/10.1056/NEJMoa1500857.
- van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 2019;139:775–786. doi:https://doi.org/10.1161/CIRCULATIONAHA.118.036248.
- Parker WAE. Aspirin after PCI: in the twilight of its years? Platelets 2020:1–3. doi:https://doi.org/10.1080/09537104.2020.1714574.
- Iantorno M, Lipinski MJ, Garcia-Garcia HM, Forrestal BJ, Rogers T, Gajanana D, Buchanan KD, Torguson R, Weintraub WS, Waksman R. Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery. Am J Cardiol 2018;122:1652–1660. doi:https://doi.org/10.1016/j.amjcard.2018.07.040.
- Parker WAE, Storey RF. Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets 2020:1–8.
- Storey RF. The long journey of individualizing antiplatelet therapy after acute coronary syndromes. Eur Heart J 2020;41:3546-3548.
- Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, et al. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets 2019;30:148–157. doi:https://doi.org/10.1080/09537104.2019.1572880.
- Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 2020;382:1208–1218. doi:https://doi.org/10.1056/NEJMoa1910021.
- Kirtane A, Kandzari DE, Mehran R, Price MJ, Simon DI, Latib A, Kedhi E, Abizaid A, Worthley S, Zaman A, et al. One month dual antiplatelet therapy in high bleeding risk patients: primary results from the ONYX ONE CLEAR study. J Am Coll Cardiol 2020;75:1097. doi:https://doi.org/10.1016/S0735-1097(20)31724-1.
- Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925–934. doi:https://doi.org/10.1046/j.1365-2141.2000.02208.x.
- Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, et al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J Am Coll Cardiol 2020;75:578–586. doi:https://doi.org/10.1016/j.jacc.2019.11.056.
- Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99:930–935. doi:https://doi.org/10.1160/TH08-01-0002.
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780–784. doi:https://doi.org/10.2337/diabetes.55.03.06.db05-1394.
- Storey RF, Angiolillo D, Patil S, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C, Becker R, Wallentin L. Inhibitory effects of ticagrelor compared to clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO PLATELET substudy. J Am Coll Cardiol 2010;56:1456–1462. doi:https://doi.org/10.1016/j.jacc.2010.03.100.
- Åstrand M, Amilon C, Röshammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamrén B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol 2019;85:413–421. doi:https://doi.org/10.1111/bcp.13812.